Atlas One · Host Biology · Scale 07 — System

Ovarian Cancer

HGSOC accounts for ~70% of ovarian cancer; BRCA1/2 mutations in ~15-20%; TP53 mutations in ~96%; olaparib and niraparib approved as maintenance; bevacizumab improves PFS; carboplatin+paclitaxel is standard frontline; PARP inhibitor maintenance is standard for HRD+ tumors.

Also known as: ovarian cancer, HGSOC, high-grade serous ovarian cancer, LGSOC, clear cell ovarian cancer, epithelial ovarian cancer, EOC, ovarian carcinoma

Scale 07 — SystemScale
draftStatus
2026-06-06Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
ovarian-cancer

Ovarian Cancer

HGSOC accounts for ~70% of ovarian cancer; BRCA1/2 mutations in ~15-20%; TP53 mutations in ~96%; olaparib and niraparib approved as maintenance; bevacizumab improves PFS; carboplatin+paclitaxel is standard frontline; PARP inhibitor maintenance is standard for HRD+ tumors.

Entry Metadata

FieldValue
IDovarian-cancer
NameOvarian Cancer
Statusdraft
Last reviewed2026-06-06
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toBrca1 connects-toPd 1 connects-toVegf connects-toMtor connects-toHereditary Breast Ovarian Cancer connects-toP53 connects-toBrca2 connects-toOvarian Clear Cell Carcinoma connects-toReproductive System connects-toEndometrial Cancer

Sources